Vaccine for Coronavirus (COVID-19)


Inovio Accelerates Timeline for Coronavirus COVID-19 DNA Vaccine INO-4800


Human Trials Planned for April. One Million Doses Expected by this Year-end
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today on 3 March 2020 announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, Coronavirus the respiratory infection the World Health Organization (WHO) has designated a Public Health Emergency of International Concern of the highest level. According to WHO, approximately 93,000 cases have been reported globally with more than 3,200 deaths.
Dr. J. Joseph Kim, Inovio's President & CEO, shared this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on March 2. Dr. Kim said, "Inovio is the leader in coronavirus vaccine development and the only company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS). Using our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19."
Dr. Kim continued, "We immediately began preclinical testing and small-scale manufacture and have already shared robust preclinical data with our public and private partners. We plan to begin human clinical trials for Vaccine in the U.S. in April and soon thereafter in China and South Korea, where the outbreak is impacting the most people. We plan on delivering one million doses of Vaccine by year-end with existing resources and capacity. However, we will need additional resources to scale up to make enough doses to help protect Americans from Coronavirus -COVID-19 as well as to lead global efforts to curtail this virus."
Inovio's COVID-19 DNA Vaccine Development Timeline

December 31, 2019
Inovio scientists learn about a novel coronavirus (SARS-CoV-2)
which caused an outbreak of the respiratory disease in Wuhan,
China now referred to as COVID-19
January 10, 2020
Chinese researchers share the genetic sequence of the novel coronavirus

Inovio designs DNA vaccine INO-4800 in three hours after
receiving the genetic sequence using its proprietary DNA
medicines platform technology


INO-4800 was designed to precisely match the DNA sequence
of the virus
January 10 to January 23, 2020
Inovio scientists’ race to manufacture INO-4800 and begin
preclinical testing
January 23, 2020
Inovio receives a grant of up to $9 million from the Coalition
for Epidemic Preparedness Innovations (CEPI) to fund ongoing
preclinical and initial clinical development of INO-4800
January 23 to February 29, 2020
Preclinical testing continues, with immune responses
generated in animal models
; human clinical trial designs
developed
March 2020
Ongoing preclinical studies; human clinical trial designs
finalized
3,000 human trial doses prepared for clinical trials
in the U.S., China, and South Korea
; large-scale manufacturing
plans developed
April 2020
Human clinical trials begin in 30 healthy volunteers in the U.S.

Human clinical trials to begin in China and South Korea
shortly thereafter
Fall 2020
Human clinical trial results presented/published
End of 2020
1 million doses of INO-4800 COVID-19 DNA vaccine produced
for further trials or emergency use

Comments

Popular posts from this blog

13 Benefits of Papaya

Novel Coronavirus Outbreak, What is Coronavirus?, How to prevent COVID-19

Health Benefits of Fenugreek Seeds.